🔎 Trials Near Me

Dachaigh › Psoriasis › Pennsylvania

Sgrùdaidhean clionaigeach Psoriasis ann an Pennsylvania

Tha 6 sgrùdaidhean airson Psoriasis a’ lorg phàirtichean aig làraichean ann an Pennsylvania.

Bailtean ann an Pennsylvania

Teacsa sgrùdaidh oifigeil (Beurla)

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UPMC Hillman Cancer Center, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT03816345

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

  • LEO Pharma Investigational Site, Philadelphia
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07013201

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • Dermatology Associates of Plymouth Meeting, Plymouth Meeting
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06857942

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  • Paddington Testing Company, Philadelphia
A’ fastadhÌre 3
Aoisean 12 gu 17 · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06979453

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

  • Study Center, Philadelphia
A’ fastadhÌre 2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 9 Iuch 2026 · NCT07489885

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

  • Temple University, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Faoi 2025 · NCT05642182

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.